Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3results about How to "High optical purity" patented technology

An imine reductase mutant, its preparation method, and its application in the catalytic preparation of dextromethorphan intermediates.

ActiveCN115927230Bhigh optical purityhigh stereoselectivityBacteriaMicroorganism based processesIsoquinolineQuinolizine
This invention provides an imine reductase mutant, its preparation method, and its application in the catalytic preparation of dextromethorphan intermediates. The imine reductase mutant is an imine reductase with an amino acid mutation, comprising the amino acid sequence shown in SEQ ID NO:1. The amino acid mutation type includes any one or a combination of at least two of I122T, D212A, or G228R. By introducing a mutation into the imine reductase, this invention significantly improves the enzyme's activity and stereoselectivity, enabling the high-yield synthesis of the dextromethorphan intermediate (S)-1-(4-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline under mild conditions, greatly reducing production costs and making it suitable for industrial production.
Owner:KINGDOMWAY BIOTECH (JIANGSU) CO LTD +2

A crystal form of phenelzine optically active intermediate IIa and its preparation method

PendingCN122079981Ahigh optical purityGood chiral resolutionOrganic chemistryPowder diffractionRay
This invention provides a novel crystalline form of phenelzine optically active intermediate IIa and its preparation method. The powder X-ray diffraction pattern of this novel crystalline form has the following characteristic diffraction angles: 8.89°, 12.78°, 19.33°, 21.43°, 22.05°, 26.77°, and 27.01°, with an error range of ±0.2° for the diffraction angle 2θ values. This invention also provides a method for preparing this novel crystalline form and its pharmaceutical applications, including its use in the preparation of phenelzine, and even its use as a chiral resolving agent in the preparation of phenelzine.
Owner:CDMO PHARM CO LTD +1

Use of an alcohol dehydrogenase in the synthesis of pharmaceutical intermediates

PendingCN122278965Ahigh optical puritymild reaction conditionsChlorobenzenePharmaceutical drug
This invention discloses an alcohol dehydrogenase derived from *Rhodotorula toruloides* and its application in the asymmetric reduction of 1-(2-chlorophenyl)-2-(1,2,3,4-tetrazol-2-yl)ethane-1-one to (R)-1-(2-chlorophenyl)-2-(1,2,3,4-tetrazol-2-yl)ethane-1-ol. The alcohol dehydrogenase can catalyze substrate conversion reactions at concentrations greater than 400 g / L, with a conversion rate >99.9% and a product ee value >99.5%. The reaction rate is fast, easily controlled, and the catalytic level is significantly improved compared to previous reports, demonstrating great potential for industrial application.
Owner:SHANGHAI AOBO PHARMTECH INC LTD